Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19704476 | 0.87 | — | — | |
| SCHEMBL13698346 | 0.86 | TDP1 (0.45) | TDP1 | |
| SCHEMBL12510344 | 0.85 | — | — | |
| SCHEMBL1193421 | 0.84 | CCNE2 (0.35) | — | |
| SCHEMBL20034671 | 0.83 | — | — | |
| SCHEMBL14037208 | 0.80 | CYP2C19 (0.42) | TDP1 | |
| SCHEMBL3461929 | 0.79 | — | — | |
| SCHEMBL2223767 | 0.79 | — | — | |
| SCHEMBL3468878 | 0.78 | TSHR (0.34) | — | |
| SCHEMBL13623137 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-06-27 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9051330-B2 | Dithiolopyrrolones with therapeutic activity | WELICHEM BIOTECH INC. (CA) | 2015-06-09 | — | — | US | disclosed |
| US-9051330-B2 | Dithiolopyrrolones with therapeutic activity | WELICHEM BIOTECH INC. (CA) | 2015-06-09 | — | — | US | disclosed |
| EP-2076519-B1 | NOVEL DITHIOLOPYRROLONES AND THEIR THERAPEUTICAL APPLICATIONS | CELESTIAL PHARMACEUTICALS SHENZHEN LTD (CN) | 2014-01-15 | — | — | EP | disclosed |
| EP-2076519-B1 | NOVEL DITHIOLOPYRROLONES AND THEIR THERAPEUTICAL APPLICATIONS | CELESTIAL PHARMACEUTICALS SHENZHEN LTD (CN) | 2014-01-15 | — | — | EP | disclosed |
| US-8071637-B2 | Dithiolopyrrolones compounds and their therapeutic applications | WELICHEM BIOTECH INC. (CA) | 2011-12-06 | — | — | US | disclosed |
| EP-1490374-B1 | DITHIOLOPYRROLONE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES | WELICHEM BIOTECH INC (CA) | 2010-09-22 | — | — | EP | disclosed |
| US-20100041729-A1 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | CELESTIAL PHARMACEUTICALS (SHENZHEN) LTD. (CN) | 2010-02-18 | — | — | US | disclosed |
| US-20060074125-A1 | Novel dithiolopyrrolones with therapeutic activity | WELICHEM BIOTECH INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| EP-1490374-A2 | DITHIOLOPYRROLONE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES | Welichem Biotech Inc. (CA) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080624-A2 | DITHIOLOPYRROLONE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES | WELICHEM BIOTECH INC. (CA) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041729-A1 | DITHIOLOPYRROLONES COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | CD4, NDUFS3, TXN2 | HTR1A 4596/4885DRD2 1440/4885HTR2A 4874/4885 |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CDH1, VIM | HTR1A 4707/4885DRD2 2973/4885HTR2A 4723/4885 |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | HTR1A 4814/4885DRD2 4497/4885HTR2A 4877/4885 |
| US-20060074125-A1 | Novel dithiolopyrrolones with therapeutic activity | TP53, DTYMK, MKI67 | HTR1A 4867/4885DRD2 4142/4885HTR2A 4877/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | HTR1A 4807/4885DRD2 4455/4885HTR2A 4872/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | HTR1A 4807/4885DRD2 4455/4885HTR2A 4872/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | HTR1A 1333/4885DRD2 2100/4885HTR2A 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.